Ranibizumab

🧮 Dose calculator

Neovascular (wet) age-related macular degeneration · Regimen source: FDA Lucentis · 2.2

• • Ophthalmologist only. Less effective alternative: 3 monthly doses then less frequent with monitoring. FDA Lucentis · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Lucentis · 8.1

  “Risk Summary There are no adequate and well-controlled studies of LUCENTIS administration in pregnant women.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Lucentis · 8.2

  “Because many drugs are excreted in human milk, and because the potential for absorption and harm to infant growth and development exists, caution should be exercised when LUCENTIS is administered to a nursing woman.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Lucentis · 8.4

  “The safety and effectiveness of LUCENTIS in pediatric patients have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Lucentis · 8.5

  “In the clinical studies, approximately 76% (2449 of 3227) of patients randomized to treatment with LUCENTIS were ≥ 65 years of age and approximately 51% (1644 of 3227) were ≥ 75 years of age [see Clinical Studies (14) ].”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Lucentis · 8.3

  “Based on the anti-VEGF mechanism of action for ranibizumab, treatment with LUCENTIS may pose a risk to reproductive capacity.”